Vymada 100 Tablet 14'S

Vymada 100 is used to manage chronic heart failure in patients with a reduced ejection fraction (HFrEF), specifically New York Heart Association (NYHA) Class II-IV. It helps reduce the risk of cardiovascular death and hospitalization caused by heart failure. Vymada works by improving the heart's efficiency and reducing the strain on the heart, helping to manage symptoms such as fatigue, breathlessness, and fluid retention.

Vymada combines two medications, Sacubitril and Valsartan, which work together to relax blood vessels by reducing resistance and allows blood to flow more easily, lowering blood pressure which helps in the management of hypertension and reducing the strain on the heart. It also improves heart function where sacubitril helps in removal of excess sodium and water, while Valsartan blocks angiotensin II, reducing vasoconstriction and preventing heart strain. Together, they enhance heart efficiency and improve quality of life in heart failure patients.

Vymada may cause reduced kidney function in some patients. Potential side effects includes increased creatinine levels, electrolyte imbalances like high potassium levels (hyperkalemia), Dizziness, fatigue, swelling, or reduced urine output.

Stopping Vymada abruptly can worsen heart failure symptoms, such as breathlessness, fluid retention, and fatigue. The heart may work less efficiently, increasing the risk of complications. Always consult your doctor before stopping or adjusting the dosage of Vymada, as a gradual change might be necessary to avoid complications.

Vymada is highly effective in managing chronic heart failure. Clinical trials, such as the PARADIGM-HF study, have shown that Vymada significantly reduces cardiovascular death risk, hospitalization rates for heart failure and symptoms of heart failure, such as fatigue and shortness of breath. It improves overall quality of life by enhancing heart function and managing fluid retention.

Valsartan, a component of Vymada, may potentially affect kidney function, particularly in patients with pre-existing kidney disease or dehydration. Therefore, patients with pre-existing kidney condition must be closely monitored.

Vymada is indicated for heart failure with reduced ejection fraction especially in patients requiring better management than conventional therapies. It is specifically designed for patients who need comprehensive management of heart function and fluid balance.

Sacubitril-Valsartan (Vymada) can be taken once or twice daily as prescribed by your doctor. While it can be taken with or without food, consistent timing helps maintain stable drug levels in your body. Consult your doctor about the optimal schedule based on your condition.

It’s important to maintain adequate hydration, but excessive water intake should be avoided, especially if your doctor has recommended fluid restrictions due to heart failure or kidney issues. Follow your doctor’s advice regarding water consumption to avoid exacerbating fluid retention or electrolyte imbalances.

Vymada is generally not associated with significant increases in blood sugar levels. However, in some patients, particularly those with diabetes, blood sugar levels may fluctuate. Regular monitoring of blood glucose is advised for diabetic patients while on Vymada.

Valsartan, a component of Vymada, can be taken at any time of day, but it is most effective when taken at the same time daily. Your doctor may recommend a specific time based on your routine, but consistency is key for optimal blood pressure and heart failure management.

Vymada 100mg helps manage chronic heart failure by improving heart efficiency, reducing symptoms like breathlessness and fatigue and lowering the risk of hospitalization and cardiovascular-related death. Its dual action on blood pressure and heart failure symptoms makes it an effective and comprehensive therapy.

Yes, Vymada lowers blood pressure by relaxing and dilating blood vessels, which decreases the workload on the heart. This helps reduce symptoms and prevents complications in heart failure patients.

Vymada is the brand name for the combination drug Sacubitril and Valsartan. In other regions, it may also be sold under the brand name Entresto.

The most common side effects include dizziness and lightheadedness due to lowered blood pressure, hypotension (low blood pressure), hyperkalemia (high potassium levels), which can cause fatigue and irregular heartbeat. Consult your doctor if you experience any of these symptoms for proper management.Bottom of Form

Yes, Valsartan is highly beneficial for the heart. It blocks the action of angiotensin II, a hormone that narrows blood vessels, leading to reduced blood pressure, decreased heart strain and improved outcomes in patients with heart failure and hypertension.